Crescendo Bioscience is developing a broad range of quantitative, objective diagnostic tools to provide Rheumatologists with deeper clinical insights to more effectively manage patients with autoimmune and inflammatory diseases.

The Company is initially focused on rheumatoid arthritis, a debilitating, highly variable, chronic disease affecting over 1.5 million patients in the US and more than 3 million in Europe. Current diagnostic tools for assessing the status of rheumatoid arthritis sufferers are largely subjective, imprecise and cumbersome to administer in daily practice. Although there is no known cure, there are multiple therapeutics with widely differing effectiveness (and adverse reactions) in individual patients. Choosing among these treatment options is a tremendous challenge

Milestones
edit

Riley Genomics received $15M in Series B funding. (6/27/08)

Posted 6/5/09 at 1:42am
Riley Genomics added Lyndal Hesterberg as CTO.

Posted 6/5/09 at 1:42am
Riley Genomics added William Hagstrom as CEO.

Posted 6/5/09 at 1:42am
Riley Genomics added Michael Centola as Chief Scientific Officer.

Posted 6/5/09 at 1:42am